brexanolone
Selected indexed studies
- Brexanolone for postpartum depression. (Am J Health Syst Pharm, 2020) [PMID:32073124]
- Brexanolone. (, 2006) [PMID:31038852]
- Brexanolone: A Novel Drug for the Treatment of Postpartum Depression. (J Pharm Pract, 2022) [PMID:33302791]
_Worker-drafted node — pending editorial review._
Connections
brexanolone is a side effect of
Sources
- Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. (2020) pubmed
- Brexanolone for postpartum depression. (2020) pubmed
- Brexanolone. (2006) pubmed
- Brexanolone: A Novel Drug for the Treatment of Postpartum Depression. (2022) pubmed
- Brexanolone. (2012) pubmed
- Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. (2019) pubmed
- Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018) pubmed
- Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. (2019) pubmed
- Brexanolone to Treat Postpartum Depression in Adult Women. (2021) pubmed
- Brexanolone. (2026) pubmed